Vertex Pharmaceuticals (VRTX) Liabilities and Shareholders Equity (2009 - 2026)

Vertex Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $26.5 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 15.75% year-over-year to $26.5 billion in Q1 2026; TTM through Mar 2026 was $101.0 billion, a 15.08% increase from a year earlier, with the FY2025 full-year figure at $25.6 billion, up 13.8% from the prior year.
• Liabilities and Shareholders Equity improved to $26.5 billion in Q1 2026 per VRTX's latest filing, from $25.6 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $26.5 billion in Q1 2026 and bottomed at $14.3 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $22.2 billion (2024), against an average of $21.2 billion.
• Across the five-year window, Liabilities and Shareholders Equity jumped 35.13% in 2022 and slipped 4.34% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $18.2 billion in 2022, then climbed by 25.23% to $22.7 billion in 2023, then slipped by 0.87% to $22.5 billion in 2024, then advanced by 13.8% to $25.6 billion in 2025, then grew by 3.28% to $26.5 billion in 2026.
• Per Business Quant, the three latest VRTX Liabilities and Shareholders Equity figures stand at $26.5 billion (Q1 2026), $25.6 billion (Q4 2025), and $24.9 billion (Q3 2025).